一种双羟萘酸雷沙吉兰长效缓释微球及其制备方法
By preparing long-acting sustained-release microspheres of rasagiline dihydroxynaphthyl acid and polylactic acid polymers, the problems of low drug loading and unstable release of rasagiline sustained-release formulations have been solved, achieving long-acting drug release and simplifying the preparation process, making it suitable for the treatment of Parkinson's disease.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- UNIV OF JINAN
- Filing Date
- 2026-03-03
- Publication Date
- 2026-07-17
AI Technical Summary
Existing rasagiline extended-release formulations suffer from low drug loading, short release cycles, severe burst release, and complex manufacturing processes, making it difficult to meet the long-term treatment needs of Parkinson's disease patients.
Long-acting sustained-release microspheres were prepared using rasagiline dihydroxynaphthyl acid and polylactic acid polymers. The drug release rate was controlled by adjusting the proportion of low molecular weight polylactic acid and lowering the curing temperature. The preparation process was simplified by using a single emulsion solvent evaporation method.
It achieves high drug loading and high encapsulation efficiency, stable drug release, and a release cycle of up to four weeks, making it suitable for industrial production, reducing biocompatibility risks, and expanding the scope of clinical application.
Smart Images
Figure CN121754491B_ABST